ABSTRACT
BACKGROUND An increase in epicardial fat thickness (EFT) has been associated with increased cardiovascular risk and the development of atherosclerosis. Transthoracic echo-cardiography provides a reliable measurement of EFT. We evaluated the relationship of EFT with carotid intima–media thickness (CIMT) and ankle–brachial index (ABI), in patients with metabolic syndrome. METHODS We assessed 80 patients with metabolic syndrome who underwent echocardiography; EFT was measured by two cardiologists. The CIMT (B-mode colour imaging of extracranial carotid arteries using high-resolution ultrasound) was also measured by a certified ultrasonographer, and ABI was measured by the main researcher. RESULTS We did not find any correlation between ABI with EFT (r=0.0103, p=0.93) or with CIMT (r=–0.1625, p=0.15). However, we found a significant correlation between EFT and CIMT (r=0.2718, r2=0.074, p=0.015). When we evaluated the risk for a CIMT >0.9 mm in patients with an EFT >3 mm, we found a statistically significant association (p=0.039). Interestingly, only 1 patient with an EFT <3 mm had a CIMT >0.9 mm. CONCLUSION We found that the EFT correlates with CIMT in patients with metabolic syndrome, which explains, at least in part, the higher risk of atherosclerosis in them. Measurement of EFT should be part of the cardiovascular risk evaluation in patients with metabolic syndrome.
ABSTRACT
Resumen: OBJETIVO: Demostrar si el índice neutrófilo/linfocito predice la mortalidad en pacientes con neumonía tipo influenza. MATERIAL Y MÉTODO: Estudio de casos y controles, observacional, analítico, transversal, retrospectivo y retrolectivo que incluyó pacientes con neumonía por influenza que padecieron neumonía aguda grave de 2009 a 2017. Se calculó APACHE II, SMART COP y el índice neutrófilo/linfocito (INL). Se determinó supervivencia mediante Kaplan y Meier, para la asociación entre INL y mortalidad, APACHE II, SMART COP y comorbilidades se usó χ2 y razón de momios (RM), así como correlación entre APACHE II, SMART COP e INL. RESULTADOS: Se incluyeron 69 pacientes. La RM entre el INL y la mortalidad fue de 0.174 (p = 0.533; IC95% 0.274 a 2.08). Hubo asociación significativa entre el INL y componentes del síndrome metabólico en pacientes vivos. No hubo diferencia en la supervivencia entre INL mayor o menor de 7. Correlación positiva entre APACHE II e INL de 0.4295 (p = 0.0002; IC95% 0.00 a 0.063). CONCLUSIONES: Existe asociación entre el INL y el síndrome metabólico en pacientes vivos, así como correlación positiva con APACHE II. No hay asociación entre el INL y mortalidad. El punto de corte del INL se desplazó cuatro puntos comparado con otras poblaciones.
Abstract: OBJECTIVE: To demonstrate if neutrophil/lymphocyte index predicts mortality in patients with influenza-like pneumonia. MATERIAL AND METHOD: A case-control, observational, analytical, cross-sectional, retrospective and retrolective study with patients with influenza like pneumonia who developed severe acute pneumonia from 2009 to 2017. APACHE II, SMART COP and neutrophil lymphocyte index (INL) were calculated. Survival was determined by Kaplan and Meier, for the association between INL and mortality, APACHE II, SMART COP and comorbidities was used χ2 and odds ratio (OR), as well as correlation between APACHE II, SMART COP and INL. RESULTS: There were included 69 patients. OR between the INL and mortality was of 0.174 (p = 0.533, IC95% 0.274-2.08). There was significant association between INL and components of the metabolic syndrome in living patients. There was no difference in survival between INL greater or less than 7. Positive correlation between APACHE II and INL of 0.4295 (p = 0.0002, IC95% 0.00 to 0.063). CONCLUSIONS: There is an association between INL and metabolic syndrome in liv- ing patients, as well as a positive correlation with APACHE II. There is no association between INL and mortality. The cutoff point of the INL shifted 4 points compared to other populations.
ABSTRACT
Resumen OBJETIVO Evaluar si hay diferencias en el grosor de la grasa epicárdica en pacientes con diabetes mellitus 2, prediabetes y sujetos no diabéticos. MATERIAL Y MÉTODO Estudio en el que de enero a agosto de 2017 se evaluaron sujetos divididos en tres grupos: sujetos con diabetes mellitus 2, sujetos con prediabetes y sujetos no diabéticos. En todos se midió el grosor de la grasa epicárdica por ecocardiografía, siguiendo la técnica descrita por Iacobelis, con un equipo Aloka alfa 6, usando un transductor de 3.5 MHz, por dos ecocardiografistas que desconocían los datos clínicos de los pacientes. El método estadístico usado fue ANOVA. RESULTADOS Se incluyeron en el estudio 120 pacientes divididos en los tres grupos (40 pacientes cada grupo); se encontró grosor de la grasa epicárdica de 5.63 mm en el grupo de diabetes mellitus, de 4.43 mm en el grupo de prediabetes y de 4.0 mm en el grupo sin diabetes. No hubo diferencia en el grosor de la grasa epicárdica entre los grupos sin diabetes y prediabéticos (p = 0.09). Sin embargo, sí encontramos diferencia significativa entre el grupo de diabetes mellitus y los grupos prediabetes y sin diabetes (p = 0.00017). CONCLUSIÓN Los pacientes diabéticos tipo 2 tienen mayor grosor de la grasa epicárdica que los prediabéticos y los sujetos no diabéticos, lo que apoya la relación entre grasa visceral y diabetes mellitus tipo 2.
Abstract OBJECTIVE To evaluate the differences in epicardial fat thickness in subjects with type-2 diabetes, prediabetes or non-diabetic. MATERIAL AND METHOD A study was done from January to August 2017 evaluating subjects divided into 3 groups: group with type-2 diabetic patients, group with subjects with prediabetes and group with nondiabetic subjects. In all of them the epicardial fat thickness was measured with an Aloka alfa 6 equipment, by 2 cardiologists who were unaware of the clinical data. Statistical analysis was performed with ANOVA. RESULTS There were included 120 patients divided into three groups of 40 patients each. Epicardial fat thickness was of 5.63 mm in diabetes mellitus group, 4.43 mm in prediabetes group and 4 mm in nondiabetic group. We did not find difference in epicardial fat thickness between nondiabetes and prediabetes groups (p = 0.09). However, we found significantly differences in epicardial fat thickness between diabetes group and groups of prediabetes and nondiabetes (p = 0.00017). CONCLUSION Type-2 diabetic patients have greater nondiabetes than prediabetic and nondiabetic subjects; this fact supports the relationship between visceral fat and the risk of type-2 diabetes.